Product
Retatrutide
Aliases
LY3437943
8 clinical trials
9 indications
Indication
Diabetes MellitusIndication
Type 2Indication
ObesityIndication
Chronic Knee PainIndication
Osteoarthritis, KneeIndication
Obstructive Sleep ApneaIndication
Type 2 DiabetesIndication
Osteoarthritis of the KneeIndication
Cardiovascular DiseasesClinical trial
A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)Status: Recruiting, Estimated PCD: 2026-12-11
Clinical trial
A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled TrialStatus: Recruiting, Estimated PCD: 2026-02-06
Clinical trial
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)Status: Recruiting, Estimated PCD: 2026-04-15
Clinical trial
A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular DiseaseStatus: Recruiting, Estimated PCD: 2026-01-20
Clinical trial
A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With or Without Metformin and/or SGLT2 InhibitorStatus: Recruiting, Estimated PCD: 2026-09-11
Clinical trial
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled TrialStatus: Recruiting, Estimated PCD: 2026-05-03
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index ≥27 kg/m^2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease.Status: Recruiting, Estimated PCD: 2029-02-01